Analyst Christopher Neyor works at JPMORGAN and is focused on the Healthcare sector with 22 price targets and ratings documented since 2017 spanning on 2 stocks. Analyst's average stock valuation to be materialised ratio is 41.67% with an average time for price targets to be met of 91.5 days.
Most recent stock forecast was given on KALA, Kala Pharmaceuticals, Inc at 30-Mar-2022.
Christopher Neyor best performing recommendations are on PCRX (PACIRA BIOSCIENCES, INC).
The best stock recommendation documented was for PCRX (PACIRA BIOSCIENCES, INC) at 11/2/2018. The price target of $50 was fulfilled within 3 days with a profit of $0.32 (0.64%) receiving and performance score of 2.12.
Average potential price target upside
Currently, out of the existing stock ratings of Christopher Neyor - 854 which are a Buy (48.03%), 116 which are a Sell (6.52%), 808 which are a Hold (45.44%)
Analyst name
Rating
Current price target
Potential distance
Previous price target
Date
Price targets met ratio
Average potential upside
Average time for PT to be met
Performance score
Buy
71
$31.86 (81.40%)
69
26 days ago
9/17 (52.94%)
$16.87 (36.05%)
236
Buy
60
$20.86 (53.30%)
63
27 days ago
9/15 (60%)
$17.34 (37.22%)
291
Buy
60
$20.86 (53.30%)
94
1 months 24 days ago
3/19 (15.79%)
$39.74 (81.67%)
1358
Hold
52
$12.86 (32.86%)
60
2 months 21 days ago
25/28 (89.29%)
$1.94 (3.07%)
65
Buy
80
$40.86 (104.39%)
90
8 months 6 days ago
16/21 (76.19%)
$12.87 (26.89%)
391
